Language

Chinese English

Home page

The Chinese GLP-1 market is about to undergo a major shift.

Mar 20,2026

In March 2026, semaglutide in China reached the “patent cliff” moment. According to registration information from the China National Intellectual Property Administration, Novo Nordisk’s core compound patent for semaglutide officially expired on March 20. Just three months earlier, Novo Nordisk had just won a significant patent counterattack: the Supreme People’s Court issued a favorable ruling on intellectual property issues related to the semaglutide compound patent, bringing an end to this protracted patent battle. However, this hard-won victory granted Novo Nordisk little more than 100 days of protection.

Dr. Zhang Dan Appointed Chief Scientist of PUMCH Innovation Harbor

Mar 18,2026

On February 2, 2026, the Inaugural Ceremony of the PUMC Innovation Hub at the Chinese Academy of Medical Sciences and Peking Union Medical College was held. The event was attended by nearly 200 guests, including diplomatic envoys accredited to China, representatives from the Ministry of Science and Technology, the National Health Commission, and relevant departments of the Beijing Municipal Government, leaders of the CPC Dongcheng District Committee and the Dongcheng District People’s Government, university leaders, academicians and expert representatives, heads of various institutes and research centers, as well as representatives from medical institutions, universities, industry associations, central and municipally owned enterprises, and partner organizations.

Set for July 22–24: The Inaugural Global Conference on Innovative Drugs of Major Countries (CPIC) is Positioned as the “Clover”

Mar 15,2026

Over the past decade, China’s innovative pharmaceutical industry has risen rapidly and become deeply integrated into the global pharmaceutical landscape, emerging as a top priority for multinational pharmaceutical companies in their pipeline strategies. In both quantity and quality, China’s innovative drugs are fully commensurate with the country’s status as a major power. Moreover, the thriving biopharmaceutical sector has, for the first time, been officially designated by the state as an “emerging pillar industry.”

In Vivo CAR-T: “Saturation-Driven Innovation” After One Year

Mar 14,2026

Since 2024, when the concept of in vivo CAR-T therapy ignited the industry, the number of domestic companies claiming to be deploying this technology has surged from dozens to over 200 in just two years, giving rise to an unprecedented wave of “saturation-level innovation.” The overseas market is equally dynamic. In February, Eli Lilly acquired Orna Therapeutics for up to $2.4 billion, Gilead Sciences secured Arcellx for $7.8 billion, and Bristol Myers Squibb, AbbVie, and AstraZeneca followed suit. Several multinationals have announced multi-billion-dollar M&A deals, pushing the potential of this technological approach to new heights.

Banking capital is pouring into innovative drugs.

Mar 13,2026

Over the past few years, the financing environment for the innovative pharmaceutical industry has endured a prolonged winter, with fundraising virtually hanging like a Sword of Damocles over the heads of every biotech founder. As the chill of that winter has begun to lift and the sector gradually recovers, observers have noticed that a previously low-profile investor has increasingly come into the spotlight.

A major pharmaceutical nation will inevitably become a leading force in new drug development.

Mar 08,2026

The national strategic status of the biopharmaceutical industry is poised for a historic upgrade! On March 5, the Government Work Report at this year’s Two Sessions explicitly designated biopharmaceuticals as an “emerging pillar industry” at the national level, placing it alongside such sectors as integrated circuits, aerospace, and the low-altitude economy. This marks the first time in the Government Work Report that the development of the biopharmaceutical industry has been positioned as a pillar industry, sending a significant policy signal to accelerate the industry’s upgrading.

< 1 2 3 4 > proceed page

Follow or Contact Us

Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.

Public Account QR Code

Registration QR Code

Conference Service Hotline

+86 10 8363 4290

© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.